CADTH Canadian drug expert committee recommendation: Cysteamine ophthalmic solution (Cystadrops -- recordati rare diseases Canada Inc.) indication : treatment of corneal cystine crystal deposits (CCCDs) in adults and children from 2 years of age with cystinosis
The CADTH Canadian Drug Expert Committee (CDEC) recommends that cysteamine hydrochloride (CH) 0.55% ophthalmic solution be reimbursed for the treatment of CCCDs in adults and children from two years of age with cystinosis only if the following conditions are met: Patient has a diagnosis of cystinosi...
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
June 2019, 2019
|
Edition: | Version: Final |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that cysteamine hydrochloride (CH) 0.55% ophthalmic solution be reimbursed for the treatment of CCCDs in adults and children from two years of age with cystinosis only if the following conditions are met: Patient has a diagnosis of cystinosis and evidence of CCCDs; Patient must be under the care of an ophthalmologist experienced in the management of the ocular manifestations of cystinosis; Reduction in price |
---|---|
Item Description: | "Final." |
Physical Description: | 1 PDF file (8 pages) |